Literature DB >> 9563797

Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma.

B Paule1, D Clerc, C Rudant, C Coulombel, L Bonhomme-Faivre, J Quillard, M Bisson.   

Abstract

Interleukin-6 (IL-6) is produced by renal cell carcinoma (RCC) cell lines and primary tumors. Using immunohistochemical staining in two RCC patients with hypercalcemia and high serum levels of free and total IL-6, we showed expression of IL-6 in metastatic bone tissue. The role of IL-6 in hypercalcemia and bone resorption would suggest that bisphosphonates or dexamethasone could be useful as adjuvant therapy for IL-6 dependent bone metastases which fail to respond to interferon alpha (IFN) alpha 2a and all trans retinoic acid (ATRA).

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9563797     DOI： 10.1016/s0046-8177(98)90128-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


  7 in total

1.  Cortical bone resorption during exercise is interleukin-6 genotype-dependent.

Authors:  Sukhbir S Dhamrait; Laurence James; David J Brull; Saul Myerson; Emma Hawe; Dudley J Pennell; Michael World; Stephen E Humphries; Fares Haddad; Hugh E Montgomery
Journal:  Eur J Appl Physiol       Date:  2002-12-24       Impact factor: 3.078

2.  The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study.

Authors:  B Paule; J Belot; C Rudant; C Coulombel; C C Abbou
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

3.  Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.

Authors:  Ken Tawara; Julia T Oxford; Cheryl L Jorcyk
Journal:  Cancer Manag Res       Date:  2011-05-18       Impact factor: 3.989

4.  Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Authors:  Yoshiaki Kawano; Wataru Takahashi; Masatoshi Eto; Tomomi Kamba; Hideaki Miyake; Masato Fujisawa; Takao Kamai; Hirotsugu Uemura; Taiji Tsukamoto; Haruhito Azuma; Akio Matsubara; Kazuo Nishimura; Tsuyoshi Nakamura; Osamu Ogawa; Seiji Naito
Journal:  Cancer Sci       Date:  2016-06-14       Impact factor: 6.716

5.  RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.

Authors:  Sam Cross-Knorr; Shaolei Lu; Kimberly Perez; Sara Guevara; Kate Brilliant; Claudio Pisano; Peter J Quesenberry; Murray B Resnick; Devasis Chatterjee
Journal:  BMC Cancer       Date:  2013-10-08       Impact factor: 4.430

6.  G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.

Authors:  Yong Wang; Donghe Fu; Yajing Chen; Jing Su; Yiting Wang; Xin Li; Wei Zhai; Yuanjie Niu; Dan Yue; Hua Geng
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

Review 7.  RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity.

Authors:  Roni Touboul; Stavroula Baritaki; Apostolos Zaravinos; Benjamin Bonavida
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.